Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tamar Peretz

Showing results (51-60 of 217) with videos related to

Pageof 22
Sort By:
Frontiers in Oncology|May 8, 2024
The functional role of Nudt2 in human triple negative breast cancerRasha Abu-Rahmah, Hovav Nechushtan, Sanaa Hidmi, et al.
Frontiers in Cell and Developmental Biology|December 22, 2022
Metabolomic profiling of triple negative breast cancer cells suggests that valproic acid can enhance the anticancer effect of cisplatinAvital Granit, Kumudesh Mishra, Dinorah Barasch, et al.
Tumori|March 10, 2010
Mitomycin C and vinblastine: an active regimen in previously treated breast cancer patientsInna Ospovat, Nava Siegelmann-Danieli, Tal Grenader, et al.
The Israel Medical Association Journal : IMAJ|November 29, 2005
Effect of breast magnetic resonance imaging on the clinical management of breast cancerDaliah Galinsky, David Kisselgoff, Tamar Sella, et al.
Anticancer Research|June 25, 2003
Prognostic factors for survival in metastatic breast cancer during first-line paclitaxel chemotherapyBenjamin Nisman, Vivian Barak, Ayala Hubert, et al.
Acta Oncologica (Stockholm, Sweden)|June 25, 2015
Is (18)F-FDG PET/CT an accurate tool for identifying metastases of lobular breast cancer?Marina Orevi, Nanette Freedman, Esther Tahover, et al.
Molecular and Clinical Oncology|May 5, 2018
Defects in homologous recombination repair genes are associated with good prognosis and clinical sensitivity to DNA-damaging agents in pancreatic cancer: A case reportAmir Sonnenblick, Aviad Zick, Myriam Maoz, et al.
Cancer Biomarkers : Section a of Disease Markers|December 24, 2010
Serum thymidine kinase 1 activity in breast cancerBenjamin Nisman, Tanir Allweis, Luna Kaduri, et al.
Familial Cancer|August 6, 2008
Absence of founder BRCA1 and BRCA2 mutations in cutaneous malignant melanoma patients of Ashkenazi originLuna Kadouri, Mark Temper, Tal Grenader, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|September 18, 2013
Cost-effectiveness of baseline low-dose computed tomography screening for lung cancer: the Israeli experienceAmir Shmueli, Shifra Fraifeld, Tamar Peretz, et al.
Pageof 22

Showing results (51-60 of 217) with videos related to

Sort By:
Pageof 22
Frontiers in Oncology|May 8, 2024
The functional role of Nudt2 in human triple negative breast cancerRasha Abu-Rahmah, Hovav Nechushtan, Sanaa Hidmi, et al.
Frontiers in Cell and Developmental Biology|December 22, 2022
Metabolomic profiling of triple negative breast cancer cells suggests that valproic acid can enhance the anticancer effect of cisplatinAvital Granit, Kumudesh Mishra, Dinorah Barasch, et al.
Tumori|March 10, 2010
Mitomycin C and vinblastine: an active regimen in previously treated breast cancer patientsInna Ospovat, Nava Siegelmann-Danieli, Tal Grenader, et al.
The Israel Medical Association Journal : IMAJ|November 29, 2005
Effect of breast magnetic resonance imaging on the clinical management of breast cancerDaliah Galinsky, David Kisselgoff, Tamar Sella, et al.
Anticancer Research|June 25, 2003
Prognostic factors for survival in metastatic breast cancer during first-line paclitaxel chemotherapyBenjamin Nisman, Vivian Barak, Ayala Hubert, et al.
Acta Oncologica (Stockholm, Sweden)|June 25, 2015
Is (18)F-FDG PET/CT an accurate tool for identifying metastases of lobular breast cancer?Marina Orevi, Nanette Freedman, Esther Tahover, et al.
Molecular and Clinical Oncology|May 5, 2018
Defects in homologous recombination repair genes are associated with good prognosis and clinical sensitivity to DNA-damaging agents in pancreatic cancer: A case reportAmir Sonnenblick, Aviad Zick, Myriam Maoz, et al.
Cancer Biomarkers : Section a of Disease Markers|December 24, 2010
Serum thymidine kinase 1 activity in breast cancerBenjamin Nisman, Tanir Allweis, Luna Kaduri, et al.
Familial Cancer|August 6, 2008
Absence of founder BRCA1 and BRCA2 mutations in cutaneous malignant melanoma patients of Ashkenazi originLuna Kadouri, Mark Temper, Tal Grenader, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|September 18, 2013
Cost-effectiveness of baseline low-dose computed tomography screening for lung cancer: the Israeli experienceAmir Shmueli, Shifra Fraifeld, Tamar Peretz, et al.
Pageof 22